Document Detail


Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
MedLine Citation:
PMID:  15603208     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthem from imatinib mesylate and a review of the literature.
Authors:
Miguel A Park; Gerald W Volcheck; Juan C Guarderas
Related Documents :
8493008 - Chronic dacryocystitis caused by mycobacterium fortuitum.
15870488 - Philadelphia-chromosome-positive t-lymphoblastic leukemia: acute leukemia or chronic my...
3861088 - Megakaryoblastic transformation of ph positive chronic granulocytic leukemia.
14651568 - Ecthyma gangrenosum caused by disseminated exserohilum in a child with leukemia: a case...
12507058 - An analysis of glyphosate data from the california environmental protection agency pest...
24374018 - Impacts of structuring the electronic health record: a systematic review protocol and r...
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Allergy and asthma proceedings : the official journal of regional and state allergy societies     Volume:  25     ISSN:  1088-5412     ISO Abbreviation:  Allergy Asthma Proc     Publication Date:    2004 Sep-Oct
Date Detail:
Created Date:  2004-12-17     Completed Date:  2005-02-22     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9603640     Medline TA:  Allergy Asthma Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  345-7     Citation Subset:  IM    
Affiliation:
Division of Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects*
Desensitization, Immunologic*
Drug Eruptions / etiology,  therapy*
Exanthema / chemically induced*,  therapy*
Humans
Male
Middle Aged
Piperazines / adverse effects*
Pyrimidines / adverse effects*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment ...
Next Document:  UV radiation-induced immunosuppression and skin cancer.